JP7473210B2 - 幹細胞由来の細胞培養物、幹細胞由来の三次元組織製品、及びそれらの製造及び使用方法 - Google Patents

幹細胞由来の細胞培養物、幹細胞由来の三次元組織製品、及びそれらの製造及び使用方法 Download PDF

Info

Publication number
JP7473210B2
JP7473210B2 JP2020563522A JP2020563522A JP7473210B2 JP 7473210 B2 JP7473210 B2 JP 7473210B2 JP 2020563522 A JP2020563522 A JP 2020563522A JP 2020563522 A JP2020563522 A JP 2020563522A JP 7473210 B2 JP7473210 B2 JP 7473210B2
Authority
JP
Japan
Prior art keywords
rpe
retinal
cells
rpe cells
3dnr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020563522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522822A (ja
JP2021522822A5 (cg-RX-API-DMAC7.html
Inventor
バレリア カント-ソラー マリア
フロレス ベルバー ミゲル
リー カン
アパリシオ ドミンゴ シルビア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Colorado Springs filed Critical University of Colorado Colorado Springs
Publication of JP2021522822A publication Critical patent/JP2021522822A/ja
Publication of JP2021522822A5 publication Critical patent/JP2021522822A5/ja
Priority to JP2024060789A priority Critical patent/JP7834367B2/ja
Application granted granted Critical
Publication of JP7473210B2 publication Critical patent/JP7473210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/083—Coculture with; Conditioned medium produced by cells of the nervous system sensory transducers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acoustics & Sound (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2020563522A 2018-05-09 2019-05-09 幹細胞由来の細胞培養物、幹細胞由来の三次元組織製品、及びそれらの製造及び使用方法 Active JP7473210B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024060789A JP7834367B2 (ja) 2018-05-09 2024-04-04 幹細胞由来の細胞培養物、幹細胞由来の三次元組織製品、及びそれらの製造及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862669133P 2018-05-09 2018-05-09
US62/669,133 2018-05-09
US201962826196P 2019-03-29 2019-03-29
US62/826,196 2019-03-29
PCT/US2019/031442 WO2019217630A1 (en) 2018-05-09 2019-05-09 Stem cell-derived cell cultures, stem cell-derived three-dimensional tissue products, and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024060789A Division JP7834367B2 (ja) 2018-05-09 2024-04-04 幹細胞由来の細胞培養物、幹細胞由来の三次元組織製品、及びそれらの製造及び使用方法

Publications (3)

Publication Number Publication Date
JP2021522822A JP2021522822A (ja) 2021-09-02
JP2021522822A5 JP2021522822A5 (cg-RX-API-DMAC7.html) 2022-06-01
JP7473210B2 true JP7473210B2 (ja) 2024-04-23

Family

ID=66625387

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563522A Active JP7473210B2 (ja) 2018-05-09 2019-05-09 幹細胞由来の細胞培養物、幹細胞由来の三次元組織製品、及びそれらの製造及び使用方法
JP2024060789A Active JP7834367B2 (ja) 2018-05-09 2024-04-04 幹細胞由来の細胞培養物、幹細胞由来の三次元組織製品、及びそれらの製造及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024060789A Active JP7834367B2 (ja) 2018-05-09 2024-04-04 幹細胞由来の細胞培養物、幹細胞由来の三次元組織製品、及びそれらの製造及び使用方法

Country Status (5)

Country Link
US (1) US20210317403A1 (cg-RX-API-DMAC7.html)
EP (1) EP3790959A1 (cg-RX-API-DMAC7.html)
JP (2) JP7473210B2 (cg-RX-API-DMAC7.html)
AU (2) AU2019266276A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019217630A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906815A1 (en) 2013-03-15 2014-09-18 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
CA3074426A1 (en) 2017-09-08 2019-03-14 Sumitomo Dainippon Pharma Co., Ltd. Cell aggregate including retinal tissue and production method therefor
WO2020218480A1 (ja) 2019-04-26 2020-10-29 国立研究開発法人理化学研究所 神経網膜と網膜色素上皮細胞とハイドロゲルとを含む複合体及びその製造方法
GB2584664B (en) * 2019-06-10 2023-05-24 Newcells Biotech Ltd Improved retinal organoids and methods of making the same
JP2025515075A (ja) * 2022-05-04 2025-05-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 光受容体移植処置のための細胞を選別する方法
WO2024143436A1 (ja) 2022-12-28 2024-07-04 株式会社VC Cell Therapy 網膜シートの製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
RU2580898C1 (ru) 2013-04-25 2016-04-10 Вуджин Инк. Ультразвуковая система измерения потока
AU2014362722B2 (en) 2013-12-11 2021-06-10 Riken Method for manufacturing ciliary marginal zone-like structure
WO2015109148A1 (en) 2014-01-16 2015-07-23 The Johns Hopkins University Methods for forming three-dimensional human retinal tissue in vitro
US20210155895A1 (en) * 2016-04-04 2021-05-27 Lineage Cell Therapeutics, Inc. Pluripotent Stem Cell-Derived 3D Retinal Tissue and Uses Thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
3D Neural Retinal/RPE Complex from Human iPS cells: a Novel Age-related Macular Degeneration Systems,Maryland STEM CELL RESEARCH FUND 2018 Annual Report,2019年01月10日,p.27,https://web.archive.org/web/20190110185300/https://www.tedcomd.com/sites/default/files/2018-12/MSCRF%202018%20Annual%20Report-Final.pdf
Extracellular vesicles released by human retinal pigment epithelium mediate increased polarised secretion of drusen proteins in response to AMD stressors,Journal of Extracellular Vesicles,2021年,e12165
Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs,Nature Communications,2014年,5:4047
Molecular characterization and functional analysis of phagocytosis by human embryonic stem cell-derived RPE cells using a novel human retinal assay,Molecular Vision,2009年,15,283-295
Self-Formation of Optic Cups and Storable Stratified Neural Retina from Human ESCs,Cell Stem Cell,2012年,Vol.10,p.771-785
Self-organizing optic-cup morphogenesis in three-dimensional culture,Nature,2011年,Vol.472,p.51-56
Three-dimensional early retinal progenitor 3D tissue constructs derived from human embryonic stem cells,Journal of Neuroscience Methods,2010年,Vol.190,p.63-70
Three-Dimensional Neuroepithelial Culture from Human Embryonic Stem Cells and Its Use for Quantitative Conversion to Retinal Pigment Epithelium,PLOS ONE,2013年,8(1),e54552

Also Published As

Publication number Publication date
EP3790959A1 (en) 2021-03-17
JP7834367B2 (ja) 2026-03-24
WO2019217630A1 (en) 2019-11-14
JP2021522822A (ja) 2021-09-02
AU2025226710A1 (en) 2025-09-25
JP2024086789A (ja) 2024-06-28
AU2019266276A1 (en) 2020-12-03
US20210317403A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
JP7834367B2 (ja) 幹細胞由来の細胞培養物、幹細胞由来の三次元組織製品、及びそれらの製造及び使用方法
US20230028133A1 (en) Methods of treating retinal diseases
KR102487142B1 (ko) 만능 세포를 분화시키는 방법
JP7162221B2 (ja) 網膜組織を含む細胞凝集体及びその製造方法
EP3047017B1 (en) Methods of mammalian retinal stem cell production and applications
CN113474451B (zh) 来自人多能干细胞的背源性少突胶质祖细胞
US11781110B2 (en) Induction of corneal endothelial cells
CN105378070A (zh) 由多能干细胞产生的光感受器和光感受器祖细胞
JP6468843B2 (ja) ヒト網膜前駆細胞の表現型プロファイル
JP2021522822A5 (cg-RX-API-DMAC7.html)
US20250009806A1 (en) Pharmaceutical composition comprising neural progenitor cells for prevention or treatment of optic neuropathy
US9969978B2 (en) Method for producing cardiomyocytes from human or mouse embryonic stem cells in a medium consisting of a serum-free medium and N2 supplement
EP2139989B1 (en) An isolated population of cells and methods of generating and using same
JP2006187281A (ja) ヒト角膜内皮細胞由来の前駆細胞、細胞凝集体及びそれら作製方法、並びに前駆細胞および細胞凝集体の移植方法
JP2015505459A (ja) ポリカプロラクトン基質を用いたヒト網膜前駆細胞からの光受容体の生成方法
Xia Retinal stem cell culture on planar scaffold for transplantation in animal models of retinal degeneration
US20220177837A1 (en) Geometric induction of pluripotency
CN121057811A (zh) 视网膜组织的制造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240404

R150 Certificate of patent or registration of utility model

Ref document number: 7473210

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150